3:35 PM
 | 
Oct 06, 2017
 |  BioCentury  |  Finance

Cancer aggregator

How MPM formed Cullinan to amass the best of its single asset cancer deal flow

MPM Capital launched Cullinan Oncology LLC to aggregate cancer assets that on their own would be too risky to build a company around. The firm believes by amassing up to 10 projects at any given time, the company can diversify its risk through killer experiments that either eliminate programs early or find new breakthrough therapies.

Cullinan emerged from stealth mode on Oct. 3 with a $150 million series A round co-led by the UBS Oncology Impact Fund, which is managed by MPM, and F2...

Read the full 414 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >